| Title |
Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers
|
|---|---|
| Published in |
Advances in Therapy, July 2015
|
| DOI | 10.1007/s12325-015-0222-4 |
| Pubmed ID | |
| Authors |
Georgios Vlasakakis, Susan L. Johnson, Jiang Lin, Xiaozhou Yao, Christopher J. Gruenloh, John P. Chism, Derek J. Nunez |
| Abstract |
Small peptides are approved as treatments for type 2 diabetes mellitus and may have utility in metabolic diseases. These peptides often have short half-lives requiring delivery either as a sustained-release formulation or via a device. The opportunity to study their pharmacokinetics using simple solution formulations delivered by continuous subcutaneous infusion may facilitate the drug development process. Here, we investigated the systemic exposure of an exemplar peptide (exenatide) when infused in healthy subjects using a Paradigm(®) Revel™ insulin infusion pump (Medtronic MiniMed). Four infusion regimens were tested: Constant 24-h infusion (16.5 μg/day), constant 7-day infusion (25.5 μg/day in Cohort 2), and two different 7-day escalation regimens (ranging from 7 to 58.5 μg/day in Cohort 1 and 25.5-58.5 μg/day in Cohort 3). While the overall exenatide pharmacokinetics were in line with those expected, the observed within-subject concentration variability was considerable. Our work identifies sources of potential pharmacokinetic variability relating to the method of delivery and the drug's formulation that will be valuable to investigators contemplating the delivery of peptides via insulin infusion pumps. GlaxoSmithKline. ClinicalTrials.gov number, NCT01857895. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 24 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 21% |
| Other | 3 | 13% |
| Student > Ph. D. Student | 3 | 13% |
| Student > Master | 2 | 8% |
| Student > Doctoral Student | 1 | 4% |
| Other | 4 | 17% |
| Unknown | 6 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 21% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 13% |
| Nursing and Health Professions | 2 | 8% |
| Agricultural and Biological Sciences | 2 | 8% |
| Social Sciences | 2 | 8% |
| Other | 3 | 13% |
| Unknown | 7 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 December 2023.
All research outputs
#4,516,320
of 22,805,349 outputs
Outputs from Advances in Therapy
#388
of 2,338 outputs
Outputs of similar age
#57,146
of 262,937 outputs
Outputs of similar age from Advances in Therapy
#2
of 22 outputs
Altmetric has tracked 22,805,349 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,338 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 262,937 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.